Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Cristina R. Ferrone

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9465-7008; OpenAlex author ID A5103094053. Sources: OpenAlex.

Their work

Papers
17 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
89
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 4 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 17

  1. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2025.109647↗
  2. ALLIANCE A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-024-15817-5↗
  3. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  4. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000003123↗
  5. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Co-author DOI 10.1111/his.14086↗
  6. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Co-author DOI 10.1158/1078-0432.ccr-18-1359↗
  7. A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02414-9↗
  8. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Co-author DOI 10.1016/j.cell.2019.05.012↗
  9. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.1914915116↗
  10. Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. Co-author DOI 10.1242/dmm.034793↗
  11. Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival. Co-author DOI 10.1371/journal.pone.0182855↗
  12. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biomaterials.2016.03.044↗
  13. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Co-author DOI 10.1038/nature14587↗
  14. Reply to letter: "Retrospective studies and pancreatic adenocarcinoma: how far can we backdate?". First author DOI 10.1097/sla.0000000000000417↗
  15. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable … Co-author DOI 10.1016/j.ijrobp.2014.03.034↗
  16. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Co-author DOI 10.1038/nature12040↗
  17. Cystic papillary pattern in pancreatic ductal adenocarcinoma: a heretofore undescribed morphologic pattern that mimics intraductal papillary mucinous carcinoma. Co-author DOI 10.1097/pas.0b013e318249ce1c↗

Closest collaborators

The 25 strongest of 89 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Motaz Qadan · 5 shared papers, 2020–2025 · strength 0.61
  2. Keith D. Lillemoe · 5 shared papers, 2017–2025 · strength 0.59
  3. Vikram Deshpande · 9 shared papers, 2012–2020 · strength 0.54
  4. Carlos F. Fernandez-del Castillo · 6 shared papers, 2012–2025 · strength 0.54
  5. Andrew Louis Warshaw · 4 shared papers, 2017–2025 · strength 0.50
  6. David Tsai Ting · 5 shared papers, 2016–2020 · strength 0.36
  7. Thomas P. Hank · 2 shared papers, 2022–2025 · strength 0.35
  8. Oliver Strobel · 2 shared papers, 2022–2025 · strength 0.35
  9. Akhil Chawla · 2 shared papers, 2020–2024 · strength 0.32
  10. Theodore Sunki Hong · 4 shared papers, 2014–2022 · strength 0.31
  11. Nabeel M. Bardeesy · 5 shared papers, 2013–2020 · strength 0.28
  12. Andrew Scott Liss · 4 shared papers, 2017–2020 · strength 0.27
  13. David P. Ryan · 4 shared papers, 2014–2022 · strength 0.27
  14. Kim C. Honselmann · 3 shared papers, 2017–2020 · strength 0.25
  15. Jennifer Yon-Li Wo · 3 shared papers, 2014–2022 · strength 0.24
  16. Jonathan Matthew Hernandez · 1 shared paper, 2024 · strength 0.24
  17. Alyssa V. Eade · 1 shared paper, 2024 · strength 0.24
  18. Klaus Sahora · 1 shared paper, 2025 · strength 0.23
  19. Martin Schindl · 1 shared paper, 2025 · strength 0.23
  20. Carl-Stephan Leonhardt · 1 shared paper, 2025 · strength 0.23
  21. Gerald W. Prager · 1 shared paper, 2025 · strength 0.23
  22. Azfar Neyaz · 3 shared papers, 2019–2020 · strength 0.22
  23. Marta Sandini · 2 shared papers, 2020–2022 · strength 0.21
  24. Bryan C. Fuchs · 3 shared papers, 2016–2020 · strength 0.20
  25. Carlos Fernández-del Castillo · 2 shared papers, 2019–2022 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.